KKR-backed Biosynth Carbosynth completed the acquisition of Pepscan.

KKR-backed Biosynth Carbosynth, a supplier of critical products and services to the life sciences industry, completed the acquisition of Pepscan, an expert provider of peptide-based products & services. Financial terms were not disclosed. "We are thrilled to be able to bring Pepscan’s outstanding peptide expertise into the group and form our new, global Peptide division. This allows us to continue to simplify the supply chains for our customers across life sciences, pharma and diagnostics, so they deal with one organization for all of their needs. Pepscan is known for their scientific knowledge and expertise and have a complementary set of manufacturing to those we have already, including GMP capabilities, so it was a perfect fit," Urs Spitz, Biosynth CEO and President.